Pilot Killed When Firefighting Plane Crashes Into Montana Reservoir While Scooping up Water

File photo of a view of a site after a Philippines Air Force Lockheed C-130 plane crashed on landing in Patikul, Sulu province, Philippines July 4, 2021. (Reuters)
File photo of a view of a site after a Philippines Air Force Lockheed C-130 plane crashed on landing in Patikul, Sulu province, Philippines July 4, 2021. (Reuters)
TT

Pilot Killed When Firefighting Plane Crashes Into Montana Reservoir While Scooping up Water

File photo of a view of a site after a Philippines Air Force Lockheed C-130 plane crashed on landing in Patikul, Sulu province, Philippines July 4, 2021. (Reuters)
File photo of a view of a site after a Philippines Air Force Lockheed C-130 plane crashed on landing in Patikul, Sulu province, Philippines July 4, 2021. (Reuters)

A pilot died when a single-engine firefighting aircraft crashed into a Montana reservoir Wednesday afternoon while scooping up water to fight a nearby blaze, officials said.

The crash was reported shortly after noon on Hauser Reservoir on the Missouri River northeast of Helena in Lewis and Clark County.

Law enforcement and search and rescue teams in boats responded, along with divers from Gallatin County, The AP reported.

Officials said later in a news conference that the “scooper” plane's pilot, a 45-year-old woman, died. They did not provide a name pending notification of next of kin who do not live in the United States, the Independent Record newspaper reported.

“This is not just coming in and flying and picking up water. These are dangerous types of environments," Lewis and Clark County Sheriff Leo Dutton said.

The Federal Aviation Administration, the National Transportation Safety Board and the U.S. Forest Service will investigate the crash of the Air Tractor AT-802, which was working for the Forest Service and contracted out of Idaho.

The pilot was part of a crew fighting the nearby Horse Ridge Fire, a 450-acre (182-hectare) human-caused blaze burning in dense timber in the Helena-Lewis and Clark National Forest about 5 miles (8 kilometers) south of the town of York. The fire started Tuesday, and the sheriff's office ordered some residents to evacuate Wednesday afternoon.

High temperatures in the Helena area have been above 90 degrees Fahrenheit (32 degrees Celsius) for several days and were forecast to reach 100 degrees (38 Celsius) on Wednesday.



Weight Loss Drug Cut Heart Failure Risk by 38% in Trial

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
TT

Weight Loss Drug Cut Heart Failure Risk by 38% in Trial

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights

Trial results show Eli Lilly's weight loss drug Zepbound reduces the risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure, the company said on Thursday as it continues to build a case for the medication's wider health benefits.

The drug, also known as tirzepatide, reduced the risk of a composite of heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death by 38% compared to a placebo, according to Reuters.

The trial enrolled 731 patients across 10 countries who have heart failure with preserved ejection fraction and obesity.

The condition "accounts for nearly half of all heart failure cases, and in the US almost 60% of those impacted also live with obesity," Jeff Emmick, Lilly senior vice president, product development, said in a statement.

Lilly said the study also showed the drug significantly improved heart failure symptoms and physical limitations.

Heart failure is a condition in which the heart is unable to pump enough blood to meet the body's needs. It is associated with a high burden of symptoms and physical limitations affecting daily life, including fatigue, shortness of breath, reduced ability to exercise and swelling of extremities.

Trial patients on tirzepatide were given weekly injections of the highest dose they could tolerate, up to 15 milligrams, and were followed for a median of two years.

The drug led to 15.7% weight loss in the combined population of people with and without type 2 diabetes, compared with 2.2% for the placebo, Lilly said. For the non-diabetes patients, weight loss was 13.9%.

Zepbound, also sold under the brand name Mounjaro for type 2 diabetes, is part of a top-selling class of drugs designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow digestion and decrease appetite.

Lilly said the most common side effects for trial patients on tirzepatide were diarrhea, nausea, constipation and vomiting.

The company said it plans to submit the heart failure results to the US Food and Drug Administration and other regulatory agencies starting later this year. The findings will also be presented at an upcoming medical meeting and submitted to a peer-reviewed journal.

Novo Nordisk has reported data showing its GLP-1 weight loss drug Wegovy reduces heart failure symptoms.